THE CLINICAL EFFECTIVENESS OF PROBIOTICS AND AUTOPROBIOTICS IN TREATMENT OF *HELICOBACTER PYLORI*-ASSOCIATED DYSPEPSIA

Ermolenko E.I.[a,b],
Molostova A.S.[a,g],
Baryshnikova N.V.[a,c,d],
Svarval A.V.[e],
Gladyshev N.S.[e,f],
Kashchenko V.A.[f,g],
Suvorov A.N.[a,f]

[a]The Federal State Budgetary Scientific Institution 'Institute of Experimental Medicine' 197376, Akademika Pavlova street, 12A, St. Petersburg, Russia
[b]North-Western State Medical University named after I.I.Mechnikov, 191015, 41, Kirochnaya street, St. Petersburg, Russia
[c]Pavlov First Saint Petersburg State Medical University, 6-8 Lva Tolstogo street, 197022 St. Petersburg, Russia.
[d]St.Petersburg State Pediatric Medical University, 2 Litovskaya street, 194100, St. Petersburg, Russia
[e]St. Petersburg Pasteur Institute, 197101, 14 Mira street, St. Petersburg, Russia
[f]Saint Petersburg State University, 199034, Universitetskaya nab., 7-9, St. Petersburg, Russia
[g]North-Western district scientific and clinical center named after L.G.Sokolov Federal Medical and Biological Agency, 194291, 4 Kultury Pr., St. Petersburg, Russia

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

ЭФФЕКТИВНОСТЬ ПРОБИОТИКОВ И АУТОПРОБИОТИКОВ В МОНОТЕРАПИИ ДИСПЕПСИИ, АССОЦИИРОВАННОЙ С ИНФЕКЦИЕЙ *HELICOBACTER PYLORI*

Ермоленко Е.И.[1,2],

Молостова А.С.[1,7],

Барышникова Н.В[1,3,4],

Сварваль А.В.[5],

Гладышев Н.С.[5, 6],

Кащенко В.А.[6, 7],

Суворов А.Н.[1, 6]

[1]ФГБНУ «Институт экспериментальной медицины», 197376, Санкт-Петербург, ул.Академика Павлова, 12А

[2]ФГБОУ ВОСЗГМУ им И.И.Мечникова, 191015, Санкт-Петербург, ул.Кирочная, д.41

[3]ФГБОУ ВО ПСПбГМУ им. акад. И.П.Павлова, 197022, Санкт-Петербург, ул.Льва Толстого, 6-8

[4]ФГБОУ ВО СПбГПМУ, 194100, Санкт-Петербург, ул.Литовская, 2

[5]ФБУН Научно- исследовательский институт эпидемиологии и микробиологии имени Пастера, 197101, Санкт-Петербург, ул.Мира, д. 14

[6]ФГБОУ ВПО Санкт- Петербургский государственный университет, 199034, Санкт- Петербург, Университетская наб., д. 7–9

[7]ФГБУ «Северо-Западный окружной научно-клинический центр имени Л.Г.Соколова», 194291, Санкт- Петербург, Проспект культуры, 4

Abstract.

The aim of our study was to evaluate the clinical performance of a monotherapy by *Enterococcus faecium* -based probiotics and indigenous autoprobiotics against *H. pylori* associated dyspepsia.

Materials and Methods. There were examined 95 patients with dyspepsia. The entire patient cohort underwent clinical evaluation including filling out the questionnaire to assess dyspepsia symptoms before and after treatment, gastric endoscopy as well as gastric multi-focal biopsy (gastric body and gastric antrum) and verification of *H. pylori* infection with the three clinical laboratory methods (biochemical, bacteriological and molecular detection). An antagonistic in vitro activity of probiotics against *H. pylori* was detected by drop plate method for probiotic strains *Enterococcus faecium* SF68 and *Bifidobacterium bifidum* (Bifiform), *Enterococcus faecium* L3 (Laminolact), and autoprobiotic strains combined with indigenous *Enterococcus faecium.* To examine an antagonistic activity of probiotics and autoprobiotics in clinical trials, we used a starter culture based on the *Enterococcus faecium* L3 strain and an autoprobiotic based on indigenous *Enterococcus faecium.* The probiotic or autoprobiotic were administered orally to patients with gastritis twice a day at dose of 50 ml (8.0 lgCFU/ml) for 20 days. *H. pylori* eradication was assessed by stool antigen test 1.5-2 months after the end of treatment.

Results. Initially the *H. pylori* infection was confirmed with 49.4% of patients. The sensitivity of *H. pylori* to the probiotics was detected in 81% of individuals for indigenous *Enterococci* (the autoprobiotic), 76% - for Laminolact, and in 62% - for Bifiform. 22 patients with previous history of allergic reactions to antibiotics used in routine *H. pylori* eradication regimens were divided in two cohorts. One cohort (10 patients) received the autoprobiotic only, another cohort (12 patients) received only probiotic. Monotherapy with autoprobiotic resulted in 100% *H. pylori* eradication, single-agent therapy with probiotic led to 60%

eradication of *H. pylori*. Dyspepsia symptoms were completely resolved in both groups of patients.

Conclusion. Our research demonstrated the sensitivity of examined *H. pylori* strains to be similar for traditional eradication treatment agents (antibiotics) and the proposed intervention agents (probiotics and autoprobiotics). An autoprobiotic monotherapy with indigenous enterococci led to higher levels of *H. pylori* eradication than with *E. farcium* L3-based probiotic agent. Our work demonstrated advantage for application of probiotics in patients with antibiotic allergies or other obstacles for the standard eradication therapy. Nonetheless, further investigation to better understand underlying mechanisms of action, as well as larger observational and randomized studies, are necessary to determine the scope of therapeutic application for probiotics and autoprobitics to eradicate *H. pylori* infection.

Key words: *Helicobacter pylori*, eradication, probiotics, autoprobiotics, enterococci, *Enterococcus faecium*

Резюме.

Цель исследования: оценка эффективности пробиотиков на основе энтерококков и индигенных энтерококков (аутопробиотиков) в монотерапии диспепсии, ассоциированной с *Helicobacter pylori*.

Материалы и методы. Мы провели обследование 95 пациентов, страдающих диспепсией. Обследование включало в себя опрос для оценки жалоб до и после лечения, фиброгастродуоденоскопию (ФГДС) с взятием биоптатов из тела и антрального отдела желудка для верификации инфекции *H. pylori* (биохимический, бактериологический и молекулярно-генетический метод). Для исследования антагонистической активности капельным методом в системе *in vitro* использовали пробиотики бифиформ (*Enterococcus faecium* SF68 и *Bifidobacterium bifidum)* и ламинолакт

(*Enterococcus faecium L3*), аутопробиотик на основе индигенного *Enterococcus faecium*. Для исследования антагонистической активности *in vivo* использовали пробиотическую закваску на основе штамма *Enterococcus faecium* L3 и аутопробиотик на основе индигенного *Enterococcus faecium* (патент РФ №2546253). Препараты назначали per os дважды в день по 50 мл (8,0 lgКОЕ/мл) на 20 дней. Контроль эрадикации проводился с использованием определения антигена микроорганизма в кале через 1,5-2 месяца после окончания лечения.

Результаты. Инфекция *H. pylori* была выявлена у 49,4 % пациентов. Определена чувствительность изолятов микроорганизма к индигенным энтерококкам (аутопробиотику) в 81%, ламинолакту - 76% и бифиформу - 62% случаев. Часть обследованных получала в качестве монотерапии пробиотик или аутопробиотик (пациенты с указанием в анамнезе на аллергические реакции на прием антибиотиков, используемых в схемах стандартной эрадикационной терапии). При использовании аутопробиотика элиминация возбудителя составила 100%, при использовании пробиотика – 60%. Купирование симптомов диспепсии было полным как при приеме пробиотика, так и аутопробиотика.

Заключение. Чувствительность исследуемых штаммов *H. pylori* к аутопробиотику и пробиотикам сравнима с чувствительностью микроорганизма к часто используемым в схемах эрадикации антибиотикам. Монотерапия аутопробиотиком на основе индигенных энтерококков показала более высокий процент элиминации возбудителя, чем применение закваски на основе штамма *E. faecium* L3. В случае невозможности использования стандартной антихеликобактерной терапии назначение как пробиотиков, так и аутопробиотиков является обоснованным. Однако необходимы дальнейшие исследования для расширения доказательной базы оценки эффективности препаратов на основе энтерококков в эрадикации *H. pylori*.

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

Ключевые слова: Helicobacter pylori, эрадикация, пробиотики, аутопробиотики, энтерококки, *Enterococcus faecium*

Introduction

Since the discovery of the role of *Helicobacter pylori* infection in the development of various diseases, particularly peptic ulcer and chronic gastritis, there has been a continuous search for improved methods of eradication of this microorganism. One potential way to improve anti-*H. pylori* treatment regimens is to include probiotics — medications (live microorganisms) that are used to improve the gut microbiota. An emerging need for new treatment agents for *H. pylori* eradication is growing in importance on the grounds of: 1) a decrease in the effectiveness of standard anti-*H. pylori* therapy due to an increase in *H. pylori* resistance to antibiotics, 2) side effects of proton pump inhibitors and antibacterial drugs, 3) reluctance of patients to take antibiotics [7]. Both international and Russian treatment guidelines allow for the use of probiotics. Both the fourth and fifth editions of the Maastricht Consensus Report state that some probiotics and prebiotics may be an effective supplement to standard eradication therapy [16, 17]. The clinical guidelines of the Russian Gastroenterological Association on the treatment of *H. pylori* infection in adults state that including probiotics in anti-*H. pylori* therapy improves therapy success and reduces the incidence of adverse events, namely remove the risk of *C. difficile*-associated diarrhea [2]. The VI Moscow Consensus of the Gastroenterological Scientific Society of Russia on the management of patients infected with *H. pylori* also emphasized that anti-*H. pylori* treatment is most effective and safe when supplemented with prebiotics or probiotics [3].

A number of meta-analyses demonstrated that the use of probiotics in addition to standard anti- *H. pylori* therapy improves both the effectiveness of eradication and reduces the frequency of side effects [15, 18, 20, 22, 24].

In addition, reduction of the side effects incidence of standard eradication therapy, some probiotics may have an antagonistic effect on *H. pylori* by inhibiting the growth of the microorganism. The undelying mechanism of descibed inhibition might be driven by producing antimicrobial products (bacteriocins, lactic acid, hydrogen peroxide and other) or by competing for survival (through colonization

resistance) [6]. This prompted studies to evaluate the effectiveness of probiotic monotherapy in the treatment of *H. pylori* infection. This kind of therapy can be recommended for people who have allergic reactions to antibiotics, who are non-compliant to antibiotic therapies, as well as for family members of patients infected with *H. pylori*.

There are many of both Russian and foreign studies confirming the promising positive results of using probiotics monotherapy to eradicate *H. pylori*, with efficacy varying from 6 to 48% [6, 9, 10, 11, 13, 14 ,19]. Probiotics are an emerging promising solution not only due to their ability to inhibit the growth of pathogenic microorganisms, but also because they are effective in restoring the composition of the gastrointestinal tract microbiota, as well as have a positive effect on the human immune system, mucus formation, and motility of the gastrointestinal tract [6].

However, the use of probiotics monotherapy, despite their high safety, also has its disadvantages: a relatively low eradication rate and a long course of treatment (1 month or more). The use of probiotic strains may not have a sufficiently significant antagonistic effect on *H. pylori* and a pronounced positive effect on the gastrointestinal microbiota, because they transit through the small intestine and colon. Moreover, it remains unclear how to choose a suitable probiotic for each individual.

Autoprobiotics, strains of normal microbiota isolated from a particular individual and designed to correct human microecology, are an innovative way to increase the effectiveness of eradication without producing negative effects on the microbiota. Autoprobiotics stay in the colon longer, which allows to reduce the time of treatment. Autoprobiotics prepared from native (indigenous) lactobacilli, bifidobacteria, or enterococci may become the drugs of choice, since immunological tolerance to them is formed from the first years of life, and they do not come into conflict with other the resident microbiota of the human body [21]. There already are studies showing the effectiveness of autoprobiotics based on indigenous strains of *Lactobacillus spp.* in the restoration and stabilization of the content of the main

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

representatives of the normal gut microbiota (*Bifidobacterium spp., Lactobacillus spp.* and autoprobiotics based on *E. coli*) in treating dysbiotic disorders caused by the use of antibacterial drugs [1, 8], as well as indigenous strains of *Enterococcus spp*. in the treatment of intestinal pathology and neurological diseases [12].

The aim of our study was to evaluate the clinical performance of a monotherapy by probiotics and autoprobiotic *Enterococcus faecium* for *H. pylori* associated dyspepsia. We also evaluated gastric microbiota characteristics in the absence and in the presence of this microorganism.

Materials and Methods

We examined 95 patients suffering from dyspepsia. Prior to commencing the study, all patients signed an informed consent to a comprehensive medical examination. The following groups were not included in the study: people who had received a course of eradication therapy within the previous two years, people who had taken antibiotics, proton pump inhibitors (PPIs), antacids, or bismuth containing drugs within the previous two weeks, as well as people with severe physical illnesses (including oncologic ailments) and/or infectious pathologies, pregnant and breastfeeding women.

The comprehensive examination prior to treatment included: survey to evaluate complaints (epigastric pain and signs of dyspepsia), gastroendoscopy, which included biopsies from gastric antrum and body to confirm *H. pylori* infection, and gastric microbiota analysis. The closing examination following the full treatment included an survey to evaluate complaints and collection of fecal samples to perform immunochromatographic stool tests for the detection of *H. pylori*.

Confirmation of Helicobacter pylori infection

Biochemical, bacteriological, immunological and genetic methods were used to confirm the presence of a pathogenic microorganism in the gastric mucosa. The result was considered positive when the infection was detected by all methods or by

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

any one ofest the methods. The effectiveness of eradication was evaluated by determining the *H. pylori* antigen in feces.

Rapid urease test

We used the AMA RUT Expert test system to evaluate the urease activity of bacteria in the biopsy specimen and the AMA RUT Reader (AMA, Russia) for detection and record keeping. The AMA RUT Expert indicator is a test-slide with a well containing a reactive element sealed with a film. The slide has special marking on it, ensuring that the test results can be processed automatically.

Bacteriological method

Pure culture of the pathogen was isolated from biopsy specimens of gastric mucosa for each participant individually. Incubation protocol for *H. pylori* isolation microaerophilic conditions at 37°C for 5 days on the surface of a special culture medium (Columbia agar with 10% horse serum and 1% IsoVitalex, bio Merieux, France). The number of viable bacteria (CFU/g) was determined by plating corresponding 10-fold serial dilutions of biopsy specimens. Antimicrobial susceptibility testing performed with the disc-diffusion method, sensitivity to probiotics was determined by the drop plate method and the two-layer agar method. The bacteriological method is the gold standard in the diagnosis of helicobacteriosis, as it does not give false positive results, is specific and informative. Application of bacteriological method allowed our team to confirm that *H. pylori* was present in the sample, as well as to determine its sensitivity to antibiotics, probiotics, and autoprobiotics.

In addition to detecting *H. pylori* infection, we also performed a comparative analysis of gastric microbiota in the presence and in the absence of *H. pylori*. The viable bacteria count (CFU/g) in gastric biopsy specimens was determined by plating corresponding tenfold serial dilutions of suspensions on a number of selective dense culture media in Petri dishes and counting the bacterial colonies after incubation (24 hours) at 37 °C. To determine the count of several genera of microorganisms such as *E. coli, Enterococcus spp., Klebsiella spp., Proteus spp., Enterobacter spp.* at the

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

same time, we used the following chromogenic selective media: Pronadisa 1424 (Spain), HiCrome Coliform Agar (India). The lactobacilli count was determined by plating the culture on the Pronadisa 1043 Agar MRS medium (Spain) and culturing in anaerobic jars with gas generating sachets (Thermo Scientific AN0025A (USA)) at 37°C for 48 hours.

Polymerase chain reaction

PCR was used to detect the *cagA* and the *vacA* genes and thereby detect *H. pylori* in the biopsy specimens. This method was chosen because it is highly precise and informative. Moreover, features of the gastric microbiota were determined by molecular genetic study (real-time PCR) using the Colonoflor test system and 16 S rRNA metagenomic analysis.

Quantitative polymerase chain reaction

Quantitative polymerase chain reaction (qPCR) was performed using the kit Colonoflor 16 («AlphaLab», Russia) corresponding to the set of marker colonic bacteria on the qPCR unit Mini-Opticon, BioRad. qPCR data on certain bacterial species were confirmed by classical bacteriology study.

Immune chromatographic test

The effect of probiotics and autoprobiotics used alone against H. pylori was evaluated by a non-invasive stool antigen test 1.5–2 months after treatment completion. Antigen determination in feces was carried out using the H&R *H. pylori* Vegal Farmaceutica S.L. test system, Spain.

Probiotic medication used for intervention

We used the probiotic autoprobiotic strains: *Enterococcus faecium* SF68 and *Bifidobacterium bifidum* (Bifiform, Ferrosan, Denmark) and (*Enterococcus faecium* L3 (Laminolact, «Avena», Russia) to study antagonistic activity *in vitro*. Antagonistic activity was determined using the drop plate method. The investigated probiotics were diluted in distilled water at a ratio of 1:100 and then added to a dish with agar on which the *H. pylori* strain was plated. Growth was assessed on day 6-7.

We used a starter culture based on the *Enterococcus faecium* L3 strain to study the antagonistic activity *in vivo.* This strain was isolated from fermented milk, deposited in *GenBank* (No SUB167269, 2 629 318 base pairs, contains 2717 genes) and in the collection of the All-Russia Research Institute for Agricultural Microbiology, *ND*-79, patent in Russia No 2220199. Genes encoding the synthesis of several bacteriocins (including enterocins A, B, Enx α, and Enx β) were found in the genome of this strain. The probiotics were administered for 20 days. The probiotic was administered per os twice a day at doses of 50 ml (8.0 lgCFU/ml).

Autoprobiotics maiking

Autoprobiotics were obtained as described in Russian patent No. 2546253 [5]: at least 1 ml fecal samples were collected from patients who had not taken antibiotics and/or probiotics for at least 10 days prior to collection; clones of indigenous strains of *Enterococcus faecium* were isolated from the samples using a culture medium containing sodium azide and crystal violet dye; then, colonies were selected based on the coloring; pure cultures were obtained by plating three pink-colored colonies with a burgundy center onto three sectors of Petri dishes with the same medium and incubated in a thermostat under aerobic conditions at t=37°C, and tested by PCR for absence of genes of pathogenicity; then, non-pathogenic clones were selected and cultured in a soy hydrolysate at no less than 10 ml per liter.

The 5% culture medium was prepared by diluting a lactose-free dry protein-vitamin mixture "Super LF" (SLF) in a small amount of distilled water heated to 40 ° C in a ratio of 1:1 until a homogeneous suspension was obtained. The resulting suspension was filtered through 4 layers of medical gauze and diluted with the remaining amount of distilled water (DW). The ratio of components by weight in the final suspension should be: DW:SLF=95.5. The resulting suspension was dispensed into 1-2 L plastic bottles and autoclaved at 120 ° C and 1.2 atm for 15-30 minutes, then cooled to a temperature of 40°C.

Seed doses were prepared by aseptically taking 50 mg of lyophilized starter culture and inoculating it with 2 ml of 5% culture medium cooled to 40°C. They

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

were then cultivated in an aerobical condition for 14-16 hours at 37°C. The grown cell culture was transferred into 300 ml of sterile 5% culture medium cooled to 40°C and incubated in a dry-air thermostat for 14-16 hours at 37°C. The resulting biomass was used as a seeding dose for 1-2 L of culture medium. The starter culture which changed the structure of hydrolysate earlier than others was selected and used to prepare two liters of individual autoprobiotic product containing at least 108 CFU per 1 ml, which was administered to the patient orally at a dose of 50 ml 2 times a day for at least 20 days.

Methods of statistical analysis of study results

Statistical processing of the results was carried out using Statistica 10 for Windows (StatSoft, USA). Nonparametric pairwise multiple-comparison was used to evaluate the effectiveness of diagnostic methods and treatments. A p-value <0.05 was considered statistically significant.

Results and discussion

Using various diagnostic methods, *H. pylori* infection was detected in 47 out of the 95 patients, or in 49.4% of the patients. The bacteriological method produced 21 positive results.

Evaluation of sensitivity of clinical isolates of Helicobacter pylori to antibiotics

We analyzed the sensitivity of the 21 isolated strains of *H. pylori* to the four antibacterial drugs most commonly used in the eradication therapy of *H. pylori*-associated diseases (Fig. 1).

The chart shows that the sensitivity to amoxicillin is the highest and reaches 100%, while sensitivity to metronidazole is half as high, with sensitivity to levofloxacin and clarithromycin falling between these two values. The data obtained are similar to the results of previous studies also conducted in St. Petersburg [4], which indicates a stable level of resistance of the pathogen to the antibacterial agents traditionally used in this region.

Evaluation of isolates of Helicobacter pylori isolates sensitivity to probiotics and autoprobiotics

The bacteriological (cultural) method also allowed to determine the sensitivity to probiotic and indigenous (autoprobiotic) strains of enterococci isolated from the fecal samples of patients prior to eradication therapy. According to the chart (Fig. 2), the highest number of clinical isolates were sensitive to indigenous enterococci (the autoprobiotic).

H. pylori sensitivity to antibiotics and probiotics allows for personalized treatment of *H. pylori*-associated dyspepsia. Such an individualized approach makes it possible to select the most effective means for both adjuvant therapy and monotherapy (if necessary).

Gastric microbiocenosis assessment in the presence or absence of Helicobacter pylori

We performed a comparative analysis of the gastric microbiota from 22 patients, 10 with positive *H. pylori*-status and 12 with negative *H. pylori*-status. The gastric microbiota of the patients from these two groups differed significantly (Fig. 3).

The chart demonstrates that bacteria from the genera *Proteus, Klebsiella* and *Enterobacter* were found only in samples collected from patients infected with *H. pylori.* We found no statistically significant correlation between the presence of *H. pylori* and *Fusobacterium spp., Faecalibacterium prausnitzii and Bacteroides fragilis, B. thetaiotaomicron, Bifidobacterium spp*.

It should be noted that when lactobacilli and enterococci were detected in the gastric samples at a concentration greater than 3 lgCFU/mL, the probability of detecting *H. pylori* was lower (Fig. 4).

Consequently, as demonstrated on Figure. 3 and Figure 4, we observe an increased presence of opportunistic pathogen belonging to the Enterobacteriaceae family combined with concurrent regress in numbers of colonies of enterococci and

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

lactobacilli (non-pathogenic microorganism) in *H. pylori*-positive patients. We suggest that observed imbalance in gastric microbiota can be attributed as an underlying cause for development of symptoms of dyspepsia and following *H. pylori*-associated diseases.

***Gut microbiome study by** qPCR*

The study was performed by comparing the following microorgamnisms (the quantitative content of representatives of the intestinal microbiota): the total number of bacteria, *Acinetobacter spp., Citrobacter spp., Escherichia coli and enteropathogenic E. coli, Proteus spp., Lactobacillus spp., Bifidobacterium spp., Bacteroides thetaiotaomicron, Bacteroides fragilis group, Clostridium difficile, Clostridium perfringens, Enterococcus spp., Faecalibacterium prausnitzii, Fusobacterium nucleatum* and *Parvimonas micra.*

Changes in the microbiota before and after therapy had no significant differences in patients receiving probiotics and autoprobiotics. When considering the composition of the microbiota before and after therapy of all patients, it was shown that the quantitative content of Ruminococcus Metanobrevibacterium. Roseburia, Eubacterium Blautia Enterococcus increased. The populations *of Prevotella, Streptococcus, Salmonella, Parvimonas Fusobacterium, Citrobacter, Klebsiella, EnterobacterBacteroides theiotaomicron* on the contrary decreased (fig. 5).

Assessment of the clinical impact in treatment of H. pylori infection

Within the main group of patients, we distinguished a separate cohort of 11 patients who previously had recorded allergic reactions to antibiotics that are used in standard eradication treatment regimens. This cohort was divided into two subgroups: one received probiotic alone (5 patients) and the other received solely autoprobiotic therapy (6 patients). The summarized results for clinical efficacy in relieving the symptoms of dyspepsia and the anti-Helicobacter activity of these drugs is demonstrated in Tables 1 and 2.

According to questionnaire assessment symptoms of dyspepsia were

completely eliminated after treatment with autoprobiotic and probiotic. The use of autoprobiotics based on indigenous enterococci alone is more effective in eradicating *H. pylori* than the use of a starter culture based on the *E. faecium* L3 strain.

Discussion

The prerequisite for this study were problems with the use of antibiotics, such as insufficient efficacy and side effects (diarrhea, nausea, bloating, allergic reactions etc.). In this study, for the first time, the possibility of using autoprobiotics in monotherapy of H. pylori-associated dyspepsia is considered.

The choice of the type of autoprobiotic was associated with the high efficiency of autoprobiotic enterococci in the correction of gut dysbiosis, therapy of irritable bowel syndrome and metabolic syndrome. In addition, this study has already revealed an inverse correlation between the presence of enterococci in stomach biopsies and enterococcus and lactobacilli.

It is not surprising that when correcting the microbiota of the gastrointestinal tract with the help of indigenous enterococci isolated from the patient's feces, the elimination of the pathogen and the disappearance of dyspeptic symptoms were observed. Previously, such effects were described with the introduction of several probiotics, among which some of the most effective were based on *Enterococcus faecium* [21].

In vitro studies have demonstrated a high sensitivity of *H. pylori* to probiotics based on enterococci, including autoprobiotic, comparable to sensitivity to antibiotics. As it was shown earlier, the effect of probiotics is associated with the production of enterocins [6].

The intake of the functional food product containing *E. faecium* L3 and the autoprobiotic starter culture containing *E. faecium* have many positive effects: the disappearance of pain syndrome, heartburn, belching, flatulence, apparently due to the normalization of the composition of the gut microbiota and *H. pylori* eradication.

The use of autoprobiotics did not reveal significant differences in the

composition of the gut microbiota after administration of probiotic *E. faecium* L3. The advantage of autoprobiotic can be the duration of the effect of autoprobiotics, established earlier [12].

Conclusion

For the investigated *H. pylori* strains the sensitivity is similar to both antibiotics used in standard eradication protocols and probiotics. The sensitivity of *H. pylori* to autoprobiotics based on indigenous enterococci is slightly higher than to probiotics. Treatment regimen with an autoprobiotic based on indigenous enterococci alone showed a higher eradication rate compared to a starter culture based on the *E. faecium* L3 strain. It is reasonable to include both probiotics and autoprobiotics in comprehensive eradication regimens due to dysbiotic changes of gastric microbiota in patients with dyspepsia and persisting *H. pylori* infection. When standard anti-helicobacter therapy cannot be used, autoprobiotics should be used as the preferred treatment. Enterococci-based drugs are the most promising for further research into the anti-Helicobacter effect of probiotics and autoprobiotics.

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

FIGURES

Figure 1. Prevalence of detected of *H. pylori* strains sensitive to antibacterial drugs

X axis: types of antibiotics

Y axis: **Prevalence** of detected *H. pylori* strains, %

Рисунок 1. Распространенность выявленных штаммов H. pylori, чувствительных к антибактериальным препаратам

Ось X: типы антибиотиков

Ось Y: Распространенность выявленных штаммов H. pylori, %



Figure 2. Prevalence of detected *H. pylori* strains sensitive to probiotics and autoprobiotics

X axis: Types of probiotics and autoprobiotics

Y axis: **Prevalence** of detected sensitive *H. pylori* strains, %

Рисунок 2. Распространенность выявленных штаммов H. pylori, чувствительных к пробиотикам и аутопробиотикам.

Ось X: Типы пробиотиков и аутопробиотиков.

Ось Y: Распространенность выявленных чувствительных штаммов H. pylori, %



Figure 3. Quantitative level of various opportunistic bacteria in gastric biopsy specimens from patients with positive and negative *H. pylori*-status.

X axis: *H. pylori*-status of patients

Y axis: level of gastric microorganisms, lgCFU/g

Рисунок 3. Количественный уровень различных условно-патогенных бактерий в образцах биопсии желудка от пациентов с положительным и отрицательным статусом H. pylori.

Ось X: H. pylori-статус пациентов

Ось Y: уровень желудочных микроорганизмов, lgКОЕ/г



ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

Figure 4. Prevalence of detected gastric *H. pylori* in patients with dyspepsia with isolated lactobacilli and enterococci.

X axis: *H. pylori*-status of patients

Y axis: **Prevalence** of isolated gastric lactobacilli and enterococci, %

Рисунок 4. Распространенность выявленной желудочной H. pylori у больных диспепсией с изолированными лактобациллами и энтерококками.

Ось X: H. pylori-статус пациентов

Ось Y: Распространенность изолированных желудочных лактобацилл и энтерококков, %



Figure 5. Gut microbiota profile before and after autoprobiotic- and probiotic-therapy of *H. pylori*+ gastitis

Рисунок 5. Профиль микробиоты кишечника до и после аутопробиотической и пробиотической терапии H. pylori+ гастита.



ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

TABLES

Table 1 Evaluation of the clinical effectiveness for autoprobiotics and probiotics in reversing symptoms in patients with *Helicobacter pylori*-associated dyspepsia

Таблица 1 Оценка клинической эффективности аутопробиотиков и пробиотиков в купировании симптомов у пациентов с Helicobacter pylori-ассоциированной диспепсией

Symptom, frequency in % Симптом, частота в %	Autoprobiotic Аутопробиотик		Probiotic Пробиотик	
	Before treatment До лечения	After treatment После лечения	Before treatment До лечения	After treatment После лечения
Eructation Отрыжка	33	0	60	0
Heartburn Изжога	50	0	60	0
Epigastric pain Боли в эпигастральной области	100	0	100	0
Bloating Вздутие живота	67	0	80	0
Nausea Тошнота	17	0	40	0

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

Table 2 Evaluation of the clinical effectiveness of autoprobiotics and probiotics in *Helicobacter pylori* eradication

Таблица 2 Оценка клинической эффективности аутопробиотиков и пробиотиков при эрадикации Helicobacter pylori

Parameters Параметры	Autoprobiotic (n=10) Аутопробиотик (n=10)	Probiotic (n=12) Пробиотик (n=12)
Effectiveness of anti-Helicobacter action: number of *H. pylori*-negative samples based on stool antigen test (immunochromatographic method), % (n) Эффективность антихеликобактерного действия: количество *H. pylori*-негативных образцов по результатам анализа кала на ангтиген (иммунохроматографический метод), % (n)	83(5)	60(2)

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

TITLE PAGE_METADATA

Блок 1. Информация об авторе ответственном за переписку

Сварваль Алена Владимировна - кандидат медицинских наук, старший научный сотрудник лаборатории идентификации патогенов, Федеральное бюджетное учреждение науки «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии имени Пастера» 197101, 14, Mira street, St. Petersburg, Russia, 197101, Санкт-Петербург, ул. Мира, д. 14, Телефон: +7 812 232 84 76, E-mail: alenasvar@rambler.ru

Svarval Alena Vladimirovna - PhD, Senior Researcher, Saint-Petersburg Pasteur Institute, 197101, 14, Mira street, St. Petersburg, Russia, 197101, Санкт-Петербург, ул. Мира, д. 14, Tel. +7 812 232 84 76, E-mail: alenasvar@rambler.ru

Блок 2. Информация об авторах

Elena I. Ermolenko - Doctor of Medical Sciences, Head, Laboratory of Biomedical Microecology; Professor, Faculty of Medical Microbiology, Department of Medical Microbiology; of Federal State Budgetary Educational Institution ‘Institute of Experimental Medicine’

Ермоленко Елена Игоревна – доктор медицинских наук, заведующий лабораторией биомедицинской микроэкологии, отдел молекулярной микробиологии Федерального государственного бюджетного научного учреждения «Институт экспериментальной медицины»

Anastasiia S. Molostova – Gastroenterologist at Federal State Budgetary Educational Institution ‘Institute of Experimental Medicine’, Junior Researcher at North-Western district scientific and clinical center named after L.G. Sokolov Federal Medical and Biological Agency

Молостова Анастасия Сергеевна - врач-гастроэнтеролог, Федерального государственного бюджетного научного учреждения «Институт экспериментальной медицины»

Natalia V. Baryshnikova – PhD, MD, Junior Researcher at Laboratory of Medical and Social Pediatric Problems at Federal State budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation; Associate Professor of Internal Diseases Department of Dental Faculty of [3]Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Researcher at Molecular Microbiology Laboratory of Federal State Budgetary Educational Institution ‘Institute of Experimental Medicine’

Барышникова Наталья Владимировна – кандидат медицинских наук, доцент, младший научный сотрудник лаборатории медико-социальных проблем педиатрии Федерального государственного бюджетного образовательного учреждения высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации; доцент кафедры внутренних болезней стоматологического факультета Федерального государственного бюджетного образовательного учреждения высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации; научный сотрудник лаборатории молекулярной микробиологии Федерального государственного бюджетного научного учреждения «Институт экспериментальной медицины»

Nikita S. Gladyshev - Researcher, Pathogen Identification Laboratory at Saint-Petersburg Pasteur Institute; student of the educational program "Medical Business", Faculty of Medicine Saint Petersburg State University

Гладышев Никита Сергеевич – студент образовательной программы «Лечебное дело», медицинского факультета ФГБОУ ВПО Санкт-Петербургский государственный университет; лаборант лаборатории идентификации патогенов, Федеральное бюджетное учреждение науки «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии имени Пастера»

Victor A. Kashchenko - Doctor of Medical Sciences, Professor, MD, Head of the Department of faculty surgery Saint Petersburg State University; Deputy Director for scientific and education work, Chief Surgeon at North-Western district scientific and clinical center named after L.G. Sokolov Federal Medical and Biological Agency

Кащенко Виктор Анатольевич - доктор медицинских наук, профессор, заведующий кафедрой факультетской хирургии ФГБОУ ВПО «Санкт-Петербургский государственный университет», заместитель генерального директора по научно-образовательной работе, главный хирург Федерального государственного бюджетного учреждения «Северо-Западный окружной научно-клинический центр имени Л.Г. Соколова Федерального медико-биологического агентства».

Alexander N. Suvorov - Doctor of Medical Sciences, Professor, MD, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Molecular Microbiology of Federal State Budgetary Educational Institution ‘Institute of Experimental Medicine’, ORCID iD 0000-0003-2312-5589, Email: alexander_suvorov1@hotmail.com

Суворов Александр Николаевич - доктор медицинских наук, профессор, чл.-корр. РАН, руководитель отдела молекулярной микробиологии Федерального государственного бюджетного научного учреждения «Институт

экспериментальной медицины», ORCID iD 0000-0003-2312-5589, Email: alexander_suvorov1@hotmail.com

Блок 3. Метаданные статьи

The clinical effectiveness of probiotics and autoprobiotics in the treatment *Helicobacter pylori*-associated dyspepsia

Эффективность пробиотиков и аутопробиотиков в монотерапии диспепсии, ассоциированной с инфекцией *Helicobacter pylori*

Сокращенное название статьи:

The treatment of *H. pylori*-associated dyspepsia

Лечение диспепсии, ассоциированной с инфекцией *H. pylori*

Key words: *Helicobacter pylori*, eradication, probiotics, autoprobiotics, enterococci, *Enterococcus faecium*

Ключевые слова: Helicobacter pylori, эрадикация, пробиотики, аутопробиотики, энтерококки, *Enterococcus faecium*

11 страниц, 1 таблица, 5 рисунков

Оригинальная статья

13.04.2022 г.

REFERENCES

Reference sequence number	Authors, title of a publication and source where it was published, publisher's imprint	Full name, title of a publication and source in English	Reference's URL
1	Боровкова Е.А., Алиева Е.В. Микробиологическое исследование микрофлоры толстого кишечника на дисбактериоз в оценке эффективности аутопробиотикотерапии. Естественные и технические науки.2020; 8 (146):24-33.	Borovkova E.A., Alieva E.V. Mikrobiologicheskoe issledovanie mikroflory tolstogo kishechnika na disbakterioz v otsenke effektivnosti autoprobiotikoterapii. Estestvennyeitekhnicheskie nauki.2020; 8 (146):24-33.	https://www.elibrary.ru/item.asp?id=44148083 [eLIBRARY ID: 44148083]
2	Ивашкин В.Т., Маев И.В., Лапина Т.Л. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28(1):55-70.	Ivashkin V.T., Mayev I.V., Lapina T.L et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross z gastroenterolgepatolkoloproktol. 2018; 28(1):55-70.	https://www.gastro-j.ru/jour/article/view/218 [doi.org/10.22416/1382-4376-2018-28-1-55-70].
3	Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и соавт. VI	Lazebnik L. B., Tkachenko E. I., Abdulganieva D. I. et al. VI national	https://www.elibrary.ru/item.asp?id=28870080

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

	национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология 2017; 138 (2): 3–21.	guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2017; 138 (2): 3–21.	[eLIBRARY ID: 28870080]
4	Симаненков В.И., Захарова Н.В., Жебрун А.Б., Сварваль А.В., Савилова И.В., Ферман Р.С. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Лечащий врач. 2015.;4:91.	SimanenkovV.I., ZakharovaN.V., ZhebrunA.B., Svarval' A.V., SavilovaI.V., FermanR.S. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniya. Lechashchii vrach. 2015.;4:91	https://www.elibrary.ru/item.asp?id=23280121& [eLIBRARYID: 23280121]
5	Симаненков В.И., Суворов А.Н., Соловьева О.И. Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженного кишечника с использованием этого продукта. Патент РФ на изобретение № 2546253 / 02.03.2015. Бюл. № 10.	Simanenkov V.I., Suvorov A.N., Solov'eva O.I. Sposob polucheniya personifitsirovannogo autoprobioticheskogo produkta I sposob lecheniya sindroma razdrazhennogo kishechnika s ispol'zovaniem etogo produkta. Patent RF naizobretenie № 2546253 / 02.03.2015. Byul. № 10.	http://www.findpatent.ru/patent/254/2546253.html

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

6	Суворов А.Н., Барышникова Н. В., Сварваль А. В., Ниязов Р. М. Возможности некоторых пробиотических штаммов в эрадикации Helicobacter pylori in vitro и in vivo. Фарматека. 2018;(2):74–8	Suvorov A.N., Baryshnikova N. V., Svarval A. V., Niyazov R. M. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Pharmateca. 2018; (2): 74–8.	https://www.elibrary.ru/item.asp?id=32530273& [eLIBRARY ID: 32530273]
7	Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacterpylori. Врач. 2012; 1:36-38.	Tkachenko E., Uspenskiy Yu., Baryshnikova N. Optimization of treatment for Helicobacter pylori-associated diseases. Vrach. 2012; 1:36-38.	https://www.elibrary.ru/item.asp?id=17632284& [eLIBRARY ID: 17632284]
8	Цапиева А.Н., Боровкова Е.А., Карасёва А.Б., Алиева Е.В., Суворов А.Н. Разработка метода идентификации индигенных лактобацилл кишечника при создании аутопробиотиков. // Вопросы детской диетологии. 2019; 17 (3): 52-59.	Tsapieva A.N., Borovkova E.A., Karaseva A.B., Alieva E.V., Suvorov A.N. Razrabotka metoda identifikatsii indigennykh laktobatsill kishechnika pri sozdanii autoprobiotikov. // Voprosydetskoidietologii. 2019; 17 (3): 52-59.	https://www.elibrary.ru/item.asp?id=41375709& [doi:10.20953/1727-5784-2019-3-52-59]
9	Boonyaritichaikij S, Kuwabara K, Nagano J, Kobayashi K, Koga Y. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention	-	https://pubmed.ncbi.nlm.nih.gov/19702850/ [doi:10.1111/j.1523-5378.2009.00675.x.]

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)

	of Helicobacter pylori infection. Helicobacter. 2009 Jun;14(3):202-7.		
10	Canducci F, Cremonini F, Armuzzi A, Di Caro S, Gabrielli M, Santarelli L, Nista E, Lupascu A, De Martini D, Gasbarrini A. Probiotics and Helicobacter pylori eradication. Dig Liver Dis. 2002 Sep; 34 Suppl2:S81-3.	-	https://pubmed.ncbi.nlm.nih.gov/12408448/ [doi:10.1016/s1590-8658(02)80172-4.]
11	Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014 Sep;9(6):649-54.	-	https://pubmed.ncbi.nlm.nih.gov/24178436/ [doi: 10.1007/s11739-013-1013-z]
12	Ermolenko E.I., Abdurasulova I.N., Kotyleva M.P., Svirido D.A., Matsulevich A.V., Karaseva A.B. Effects of Indigenous Enterococci on the Intestinal Microbiota and the Behavior of Rats // Neuroscience and Behavioral Physiology, 2018, 48(4):496–505.	-	https://www.elibrary.ru/item.asp?id=35499976& [doi: 10.1007/s11055-018-0591-7]
13	Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori.	-	https://pubmed.ncbi.nlm.nih.gov/16421034/ [doi: 10.1111/j.1651-2227.2005.tb01848.x.]

	ActaPaediatr. 2005 Dec;94(12):1747-51.		
14	Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018 Jan 7;24(1):139-149.	-	https://pubmed.ncbi.nlm.nih.gov/29358890/ [doi: 10.3748/wjg.v24.i1.139.]
15	Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 Oct 10;11(10):e0163743.	-	https://pubmed.ncbi.nlm.nih.gov/27723762/ [doi: 10.1371/journal.pone.0163743.]
16	Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64.	-	https://pubmed.ncbi.nlm.nih.gov/22491499/ [doi: 10.1136/gutjnl-2012-302084.]
17	Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht	-	https://pubmed.ncbi.nlm.nih.gov/27707777/ [doi: 10.1136/gutjnl-2016-312288.]

	V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30.		
18	Molina-Infante J, Gisbert JP. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev EspEnferm Dig. 2013 Sep;105(8):441-4.	-	https://pubmed.ncbi.nlm.nih.gov/24274440/ [doi: 10.4321/s1130-01082013000800001.]
19	Rosania R, Minenna MF, Giorgio F, Facciorusso A, De Francesco V, Hassan C, Panella C, Ierardi E. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets. 2012 Jun;11(3):244-9.	-	https://pubmed.ncbi.nlm.nih.gov/22452604/ [doi: 10.2174/18715281280039269 8.]
20	Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019 Apr;98(15):e15180		https://pubmed.ncbi.nlm.nih.gov/30985706/ [doi: 10.1097/MD.0000000000015 180]
21	Suvorov A, Karaseva A, Kotyleva M et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front Microbiol. 2018; Sep 12; 9:1869.		https://pubmed.ncbi.nlm.nih.gov/30258408/ [doi: 10.3389/fmicb.2018.01869]

22	Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment PharmacolTher. 2010 Nov;32(9):1069-79.	-	https://pubmed.ncbi.nlm.nih.gov/21039671/ [doi: 10.1111/j.1365-2036.2010.04457.x.]
23	Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res HepatolGastroenterol. 2017 Sep;41(4):466-475.	-	https://pubmed.ncbi.nlm.nih.gov/28552432/ [doi: 10.1016/j.clinre.2017.04.004.]
24	Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015 Apr 14;21(14):4345-57.	-	https://pubmed.ncbi.nlm.nih.gov/25892886/ [doi: 10.3748/wjg.v21.i14.4345.]

ISSN 2220-7619 (Print)
ISSN 2313-7398 (Online)